CVS Health Corp. (NYSE:CVS)

Economic profit remained consistently negative throughout the five-year period from 2020 to 2024, indicating that the company failed to generate returns in excess of its cost of capital. The persistent negative values suggest a continuous destruction of economic value over the analyzed timeframe.

Net Operating Profit After Taxes (NOPAT)

NOPAT demonstrated significant volatility. After remaining stable between 2020 and 2021, a substantial decrease occurred in 2022, with values falling to 3,871 million. A recovery was observed in 2023, reaching a peak of 9,523 million, followed by another decline to 5,319 million in 2024.

Cost of Capital and Invested Capital

The cost of capital trended upward from 7.73% in 2020 to a peak of 9.09% in 2022, before gradually moderating to 8.12% by 2024. Invested capital fluctuated moderately, declining from 136,669 million in 2020 to a low of 123,703 million in 2022, and subsequently increasing to 134,694 million in 2023 before settling at 131,642 million in 2024.

Economic Profit Volatility

The most pronounced economic loss occurred in 2022, reaching 7,379 million. This coincided with the period of lowest NOPAT and the highest cost of capital. While 2023 showed a notable improvement, with the loss narrowing to 1,866 million due to a surge in NOPAT, the trend deteriorated again in 2024, resulting in an economic loss of 5,370 million.

Net income attributable to CVS Health

The net income exhibited fluctuations over the five-year period. Starting at $7,179 million in 2020, there was an increase to $7,910 million in 2021, indicating growth. However, in 2022, net income notably declined to $4,149 million, reflecting a significant drop. This was followed by a rebound in 2023, reaching $8,344 million, which represents the highest point in the period. In 2024, net income once again decreased to $4,614 million, showing volatility and an overall irregular pattern in earnings.

Net operating profit after taxes (NOPAT)

NOPAT followed a pattern broadly similar to net income but with less pronounced volatility. It began at $9,067 million in 2020 and slightly increased to $9,170 million in 2021. In 2022, there was a sharp decline to $3,871 million, mirroring the net income decline of that year. The subsequent year, 2023, saw a recovery to $9,523 million, the highest level observed in this timeframe. By 2024, NOPAT decreased again to $5,319 million. This trend suggests that while operating profitability is subject to cyclical pressures, it remains relatively strong when it rebounds.

Insights

The data reveals substantial volatility in both net income and NOPAT with synchronous fluctuations particularly pronounced in 2022 and 2024. These troughs could indicate periods of operational or market challenges impacting profitability. Despite these downturns, the company demonstrated resilience with robust recoveries in 2023, suggesting effective management responses or favorable market conditions during that year. The gap between net income and NOPAT levels also suggests that non-operating factors or tax impacts may play a role in overall profitability fluctuations. The irregular pattern underscores the importance of closely monitoring operational efficiency and external factors influencing financial performance.

Income Tax Provision

The income tax provision exhibited a fluctuating trend over the years observed. It decreased from $2,569 million in 2020 to $2,522 million in 2021, indicating a slight reduction. This was followed by a more significant decline to $1,463 million in 2022. However, in 2023, the provision increased sharply to $2,805 million, before decreasing again to $1,562 million in 2024. Overall, the income tax provision shows variability with notable peaks and troughs during the five-year period.

Cash Operating Taxes

Cash operating taxes showed a moderate decline from $3,769 million in 2020 to $3,407 million in 2021. In 2022, there was an increase to $4,013 million, marking the highest point in the period reviewed. Subsequently, the amount slightly decreased to $3,965 million in 2023, followed by a significant drop to $2,464 million in 2024. This pattern indicates some volatility with an overall downward movement towards the end of the period.

Comparative Insights

Both income tax provision and cash operating taxes demonstrate considerable year-to-year fluctuations. Cash operating taxes consistently remained higher than the income tax provision across all years. The disparity between the two measures also varied, with the smallest gap occurring in 2024. This suggests possible changes in tax planning, timing differences, or cash tax payments relative to accounting tax expense over the evaluated periods.

Total reported debt & leases

The total reported debt and leases decreased from 85,042 million US dollars at the end of 2020 to 70,732 million US dollars by the end of 2022. This decline indicates a reduction in leverage during this period. However, starting from 2023, there is a notable increase, rising to 79,385 million US dollars and further to 82,920 million US dollars by the end of 2024, suggesting renewed borrowing or leasing commitments.

Total CVS Health shareholders’ equity

Shareholders’ equity showed a rising trend from 69,389 million US dollars in 2020, peaking at 75,075 million in 2021. Following this peak, equity experienced a slight pullback to 71,015 million in 2022 but recovered to 76,461 million in 2023. By 2024, it marginally declined again to 75,560 million US dollars. Overall, equity levels remained relatively stable with moderate fluctuations around the mid-70 billion range in the most recent years.

Invested capital

Invested capital declined steadily from 136,669 million US dollars in 2020 to 123,703 million in 2022, reflecting overall reductions in capital employed. This trend reversed in 2023 with an increase to 134,694 million followed by a slight decrease to 131,642 million in 2024. The pattern suggests a cycle of divestments or asset optimization up to 2022 and subsequent reinvestment or capital expansion over the following years, indicating adjustments in capital structure or operational focus.

The financial performance from 2020 through 2024 is characterized by a consistent inability to generate positive economic profit, indicating that the company failed to create value above its cost of capital throughout the period.

Economic Profit Trends

Economic profit remained negative for all five years, exhibiting significant volatility. Losses expanded from -1,498 million USD in 2020 to a peak deficit of -7,379 million USD in 2022. Although a substantial recovery was observed in 2023, with losses narrowing to -1,866 million USD, this improvement was not sustained, as economic profit fell again to -5,370 million USD by the end of 2024.

Invested Capital Stability

Invested capital demonstrated relative stability, fluctuating within a range of approximately 13 billion USD. The capital base decreased from 136,669 million USD in 2020 to a low of 123,703 million USD in 2022, before rising to 134,694 million USD in 2023 and settling at 131,642 million USD in 2024. The lack of aggressive growth or contraction in the capital base suggests that the fluctuations in economic profit were driven by operational returns rather than significant changes in the scale of investment.

Economic Spread Ratio Analysis

The economic spread ratio mirrors the trajectory of economic profit, remaining negative throughout the analysis period. The ratio deteriorated from -1.10% in 2020 to -5.97% in 2022, marking the period of greatest value destruction. A partial correction occurred in 2023, where the ratio improved to -1.39%, followed by a decline to -4.08% in 2024. This persistent negative spread confirms that the return on invested capital consistently remained below the weighted average cost of capital.

Overall, the data reveals a pattern of inconsistent value creation. The significant dip in 2022 and the subsequent decline in 2024 suggest recurring challenges in optimizing the return on invested capital relative to the cost of funding.

An analysis of the financial performance from 2020 through 2024 reveals a consistent failure to achieve positive economic profit, indicating that the returns generated were insufficient to cover the cost of capital throughout the period.

Revenue Growth

A sustained upward trajectory in revenues from customers is observed, with figures increasing from 267,908 million US dollars in 2020 to 370,656 million US dollars by 2024. This represents a continuous expansion of the top line over the five-year horizon.

Economic Profit Trends

Economic profit remained negative across all observed years, characterized by significant volatility. The most pronounced deficit occurred in 2022, reaching -7,379 million US dollars. Although a recovery was noted in 2023, with the deficit narrowing to -1,866 million US dollars, the performance deteriorated again in 2024, ending at -5,370 million US dollars.

Economic Profit Margin Analysis

The economic profit margin mirrors the volatility of the economic profit while accounting for the increase in revenue. The margin widened from -0.56% in 2020 to a peak deficit of -2.29% in 2022. A relative improvement was achieved in 2023, where the margin reached -0.52%, before declining to -1.45% in 2024. The divergence between steady revenue growth and the fluctuating, negative economic profit margin suggests that capital charges or operational inefficiencies have persisted despite the growth in scale.